CN103068973A - 表达Th1特性和溶细胞性质的细胞 - Google Patents

表达Th1特性和溶细胞性质的细胞 Download PDF

Info

Publication number
CN103068973A
CN103068973A CN2011800402324A CN201180040232A CN103068973A CN 103068973 A CN103068973 A CN 103068973A CN 2011800402324 A CN2011800402324 A CN 2011800402324A CN 201180040232 A CN201180040232 A CN 201180040232A CN 103068973 A CN103068973 A CN 103068973A
Authority
CN
China
Prior art keywords
cell
cells
composition
killer
killer cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800402324A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈-诺伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Priority to CN201810168834.1A priority Critical patent/CN108245673A/zh
Publication of CN103068973A publication Critical patent/CN103068973A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
CN2011800402324A 2010-08-20 2011-08-22 表达Th1特性和溶细胞性质的细胞 Pending CN103068973A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810168834.1A CN108245673A (zh) 2010-08-20 2011-08-22 表达Th1特性和溶细胞性质的细胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US61/401,881 2010-08-20
US201161495055P 2011-06-09 2011-06-09
US61/495,055 2011-06-09
PCT/US2011/048578 WO2012024666A2 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810168834.1A Division CN108245673A (zh) 2010-08-20 2011-08-22 表达Th1特性和溶细胞性质的细胞

Publications (1)

Publication Number Publication Date
CN103068973A true CN103068973A (zh) 2013-04-24

Family

ID=45594250

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800402324A Pending CN103068973A (zh) 2010-08-20 2011-08-22 表达Th1特性和溶细胞性质的细胞
CN201810168834.1A Pending CN108245673A (zh) 2010-08-20 2011-08-22 表达Th1特性和溶细胞性质的细胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810168834.1A Pending CN108245673A (zh) 2010-08-20 2011-08-22 表达Th1特性和溶细胞性质的细胞

Country Status (19)

Country Link
US (3) US20120045423A1 (https=)
EP (1) EP2606125B1 (https=)
JP (2) JP6408219B2 (https=)
KR (1) KR101900807B1 (https=)
CN (2) CN103068973A (https=)
AU (1) AU2011291477B2 (https=)
BR (1) BR112013003989B1 (https=)
CA (1) CA2808873C (https=)
DK (1) DK2606125T3 (https=)
ES (1) ES2660577T3 (https=)
HU (1) HUE036094T2 (https=)
IL (1) IL224813B (https=)
NO (1) NO2606125T3 (https=)
PH (1) PH12013500519B1 (https=)
PL (1) PL2606125T3 (https=)
PT (1) PT2606125T (https=)
SG (2) SG10201510524TA (https=)
TR (1) TR201802334T4 (https=)
WO (1) WO2012024666A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002039A (zh) * 2014-11-26 2017-08-01 Gc细胞治疗 使用t细胞用于培养自然杀伤细胞的方法
US12203065B2 (en) 2017-05-26 2025-01-21 GC Cell Corporation Method for culturing natural killer cell, using transformed T cell
US12398372B2 (en) 2018-11-14 2025-08-26 GC Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed T-cells

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660577T3 (es) * 2010-08-20 2018-03-23 Immunovative Therapies, Ltd. Células que expresan características y propiedades citolíticas de Th1
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
ES2340270T3 (es) 2002-08-23 2010-06-01 Gabriele Prof. Dr. Multhoff Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales.
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
CA2555714C (en) * 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
ES2660577T3 (es) 2010-08-20 2018-03-23 Immunovative Therapies, Ltd. Células que expresan características y propiedades citolíticas de Th1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREAS HOMBACH ET AL.: "Human CD4+T Cells lyse target cells via granzyme/perforin upon circumvention of MHC Class II restriction by an antibody-like immunoreceptor.", 《J IMMUNOL》 *
DEBORAH M. BROWN ET AL.: "IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells.", 《CELLULAR IMMUNOLOGY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002039A (zh) * 2014-11-26 2017-08-01 Gc细胞治疗 使用t细胞用于培养自然杀伤细胞的方法
CN107002039B (zh) * 2014-11-26 2021-04-23 Gc细胞治疗 使用t细胞用于培养自然杀伤细胞的方法
US11766456B2 (en) 2014-11-26 2023-09-26 GC Cell Corporation Method for culturing natural killer cells using T cells
US12203065B2 (en) 2017-05-26 2025-01-21 GC Cell Corporation Method for culturing natural killer cell, using transformed T cell
US12398372B2 (en) 2018-11-14 2025-08-26 GC Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed T-cells

Also Published As

Publication number Publication date
NO2606125T3 (https=) 2018-04-21
JP2013536232A (ja) 2013-09-19
KR20130103485A (ko) 2013-09-23
US20130195825A1 (en) 2013-08-01
BR112013003989B1 (pt) 2020-11-24
JP2017061558A (ja) 2017-03-30
SG10201510524TA (en) 2016-01-28
EP2606125A4 (en) 2014-03-19
AU2011291477B2 (en) 2016-07-28
PH12013500519A1 (en) 2013-05-06
JP6408219B2 (ja) 2018-10-17
US20130196428A1 (en) 2013-08-01
PT2606125T (pt) 2018-02-27
EP2606125B1 (en) 2017-11-22
PH12013500519B1 (en) 2020-06-26
AU2011291477A1 (en) 2013-04-04
SG187846A1 (en) 2013-03-28
CA2808873A1 (en) 2012-02-23
DK2606125T3 (en) 2018-03-05
PL2606125T3 (pl) 2018-05-30
CA2808873C (en) 2020-02-18
ES2660577T3 (es) 2018-03-23
US20120045423A1 (en) 2012-02-23
KR101900807B1 (ko) 2018-11-08
BR112013003989A2 (pt) 2017-11-14
IL224813B (en) 2020-06-30
CN108245673A (zh) 2018-07-06
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
EP2606125A2 (en) 2013-06-26
WO2012024666A2 (en) 2012-02-23
JP6525946B2 (ja) 2019-06-05
TR201802334T4 (tr) 2018-03-21
HUE036094T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
US10806777B2 (en) Method for allogeneic cell therapy
JP6525946B2 (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
HK1257638A1 (en) Cells expressing th1 characteristics and cytolytic properties
HK1184498A (en) Cells expressing th1 characteristics and cytolytic properties

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184498

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130424

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1184498

Country of ref document: HK